Related Experiment Video
Updated: Jul 9, 2026

Bacterial Inner-membrane Display for Screening a Library of Antibody Fragments
Published on: October 15, 2016
A novel bivalent single-chain variable fragment (scFV) inhibits the action of tumour necrosis factor alpha
Mengyuan Liu1, Xiangbin Wang, Changcheng Yin
1Center for Infection and Immunity Research, School of Life Sciences, Hubei University, Wuhan 430062, People's Republic of China.
Abstract:
Suppression of TNFalpha (tumour necrosis factor alpha) activity is widely considered to be among the most efficient treatments available for chronic inflammatory diseases. Here, a bivalent scFv (single-chain variable fragment) fragment, named TNF-BAb, was engineered by fusing two anti-TNFalpha scFV fragments in tandem via a long and flexible linking peptide derived from human serum albumin and produced in functional form from Escherichia coli inclusion bodies. The bioactivity assays demonstrated that TNF-BAb gained enormously in avidity and showed a much stronger ability to inhibit the biological action of TNFalpha, indicating that TNF-BAb may become a good candidate for anti-TNFalpha therapy.
More Related Videos
Related Concept Videos
Tumor Immunotherapy
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...

